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OBJECTIVE—Homocysteinemia may play an etiologic role in
the pathogenesis of type 2 diabetes by promoting oxidative
stress, systemic inﬂammation, and endothelial dysfunction. We
investigated whether homocysteine-lowering treatment by B
vitamin supplementation prevents the risk of type 2 diabetes.
RESEARCH DESIGN AND METHODS—The Women’s Anti-
oxidant and Folic Acid Cardiovascular Study (WAFACS), a
randomized, double-blind, placebo-controlled trial of 5,442 fe-
male health professionals aged 40 years with a history of
cardiovascular disease (CVD) or three or more CVD risk factors,
included 4,252 women free of diabetes at baseline. Participants
were randomly assigned to either an active treatment group
(daily intake of a combination pill of 2.5 mg folic acid, 50 mg
vitamin B6, and 1 mg vitamin B12) or to the placebo group.
RESULTS—During a median follow-up of 7.3 years, 504 women
had an incident diagnosis of type 2 diabetes. Overall, there was
no signiﬁcant difference between the active treatment group and
the placebo group in diabetes risk (relative risk 0.94 [95% CI
0.79–1.11]; P  0.46), despite signiﬁcant lowering of homocys-
teine levels. Also, there was no evidence for effect modiﬁcations
by baseline intakes of dietary folate, vitamin B6, and vitamin B12.
In a sensitivity analysis, the null result remained for women
compliant with their study pills (0.92 [0.76–1.10]; P  0.36).
CONCLUSIONS—Lowering homocysteine levels by daily sup-
plementation with folic acid and vitamins B6 and B12 did not
reduce the risk of developing type 2 diabetes among women at
high risk for CVD. Diabetes 58:1921–1928, 2009
H
omocysteinemia may promote insulin resis-
tance and -cell dysfunction through its ad-
verse metabolic effects, ultimately contributing
to the pathogenesis of type 2 diabetes and
associated complications (1–3). Several lines of evidence
from both in vitro and in vivo studies support this hypoth-
esis. First, homocysteinemia directly elicits oxidative
stress by increasing reactive oxygen species production
and diminishing intracellular antioxidant defense (2). Ex-
perimental studies have suggested that oxidative stress
interferes with insulin signaling and impairs pancreatic
-cell insulin secretion (4,5), thereby accelerating the
progression from insulin resistance to overt type 2 diabe-
tes. Second, elevated levels of homocysteine promote
systemic inﬂammation via the activation of a cascade of
inﬂammatory pathways including interleukin-6, tumor ne-
crosis factor-, and adhesion molecules (3). Low-grade
chronic inﬂammation, as reﬂected by elevated circulating
levels of inﬂammatory cytokines, may promote insulin
resistance in liver, skeletal muscle, and vascular endothe-
lium (6,7). Last, homocysteine can exert its damaging
effects on the endothelium through mechanisms involving
impaired nitric oxide (NO)-dependent vasodilation, endo-
thelial toxicity and injury, oxidative stress, and systemic
inﬂammation (2,8). The resultant endothelial dysfunction,
especially in the capillary and arteriolar endothelium, can
reduce insulin delivery to insulin-sensitive peripheral tis-
sues, which in turn impairs insulin-mediated glucose me-
tabolism (9–11). Collectively, we speculate that elevated
homocysteine levels may play an etiologic role in the
development of insulin resistance and type 2 diabetes
primarily by promoting oxidative stress, systemic inﬂam-
mation, and endothelial dysfunction.
Homocysteinemia has been recognized as a vascular
risk factor for diabetic angiopathy (12), whereas few
human data are currently available on the relation be-
tween homocysteine levels and risk of developing type 2
diabetes. In observational studies, homocysteine levels in
nondiabetic individuals have been positively correlated
with several biomarkers of insulin resistance and/or glu-
cose intolerance in some (13–15) but not all (16–18)
studies. In a 4-year prospective cohort study, elevated
levels of homocysteine were independently associated
with a 3.6-fold increased risk of type 2 diabetes among 170
women with a history of gestational diabetes mellitus (19).
These observations not only provided suggestive evidence
linking elevated levels of homocysteine to the develop-
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DIABETES, VOL. 58, AUGUST 2009 1921ment of type 2 diabetes but also led to the suggestion that
lowering homocysteine levels may prevent or reduce risk
of type 2 diabetes.
Dietary folic acid and vitamins B6 and B12 are the most
important modiﬁable determinants of homocysteine lev-
els, and adequate intake of B vitamins may be potentially
beneﬁcial for prevention of type 2 diabetes in the general
population. However, no previous prospective cohort
studies have speciﬁcally examined intakes of individual B
vitamins and diabetes risk. Some small and short-term
randomized trials for secondary prevention of diabetes
complications have been conducted but yielded inconsis-
tent results; some reported that folic acid supplementation
(5–10 mg/day) reduced oxidative stress and improved
endothelial function in diabetic patients during a period of
2–12 weeks (20–23). To the best of our knowledge, there
are no previous randomized clinical trials assessing the
efﬁcacy of B vitamin supplements for primary prevention
of type 2 diabetes. In a large cardiovascular disease (CVD)
prevention trial, the Women’s Antioxidant and Folic Acid
Cardiovascular Study (WAFACS), we speciﬁcally exam-
ined the homocysteine-lowering effect by daily supplemen-
tation with folic acid, vitamin B6, and vitamin B12 on the
risk of type 2 diabetes in women at high risk for CVD.
RESEARCH DESIGN AND METHODS
The WAFACS is a randomized, double-blind, placebo-controlled trial evaluat-
ing the effects of a combination pill of folic acid (2.5 mg/day), vitamin B6 (50
mg/day), and vitamin B12 (1 mg/day) in the secondary prevention of important
vascular events among high-risk women with either a history of CVD or at
least three cardiovascular risk factors. Brieﬂy, the WAFACS began in 1998,
when the folic acid, vitamin B6, and vitamin B12 component was added to the
Women’s Antioxidant Cardiovascular Study (WACS), an ongoing 222
factorial trial of three antioxidant vitamins (vitamins C and E and -carotene),
which expanded it to a four-group factorial trial. Details of the overall trial
design and the main results from the WAFACS and WACS have been reported
previously (24–26). The study was sponsored by the National Heart, Lung, and
Blood Institute of the National Institutes of Health. The study vitamins and
matching placebo were provided by BASF Corporation (Mount Olive, NJ). The
trial was approved by the institutional review board of Brigham and Women’s
Hospital (Boston, MA), and all patients provided written informed consent. An
external independent data and safety-monitoring board monitored the safety
of the participants and the overall quality and scientiﬁc integrity of the study.
In the WACS parent trial, 8,171 female health professionals were random-
ized into the trial from June 1995 through October 1996 to receive vitamin C
(500 mg/day), vitamin E (600 IU every other day), and -carotene (50 mg every
other day) versus respective matching placebos. Women were eligible for
WACS if they were at least 40 years old, postmenopausal or had no intention
of becoming pregnant, and had a self-reported history of CVD (including
myocardial infarction, stroke, coronary revascularization, or angina) or had at
least three traditional cardiac risk factors (26).
In April 1998, 5,442 of these women provided consent and were addition-
ally randomized in a factorial design to receive a combination pill containing
2.5 mg folic acid, 50 mg vitamin B6, and 1 mg vitamin B12 (active treatment)
or a matching placebo daily. All study investigators, staff, and participants
were unaware of the participants’ treatment assignments. From the 5,442
women randomized in the WAFACS trial, we excluded those with diabetes at
baseline (n  1,190) for the present analyses, leaving 4,252 nondiabetic
women at baseline (Fig. 1).
Follow-up procedures. Following randomization and annually thereafter,
participants were mailed monthly calendar packs containing active agents or
placebos, along with questionnaires on adherence, use of nonstudy supple-
ments, and occurrence of major illnesses or adverse events. A semiquantita-
tive food-frequency questionnaire at baseline was used to assess dietary
nutrient intake (27). Written permission for medical records was sought from
participants who reported cardiovascular end points or from the next of kin in
case of death. Death certiﬁcates were also obtained. An end points committee
of physicians who were blinded to randomized treatment assignment adjudi-
cated all primary and secondary cardiovascular outcome events. Study
medications and end point ascertainment were continued in a blinded fashion
until the scheduled end of the trial, 31 July 2005, for a follow-up duration of 7.3
years. At the scheduled end of the trial, morbidity and mortality follow-up was
92.6% complete. If assessed in terms of person-time, mortality and morbidity
information was complete for 98.9 and 98.0%, respectively, of person-years of
follow-up.
8171 Women Randomized in the WACS Trial 
(June 1995-January 31, 2005)
5442 Randomized in the 
WAFACS Trial 
(April 1998-July 31, 2005)
Daily take of a combination pill of folic 
acid, vitamin B6, and vitamin B12
(n=2721)
Daily intake of a placebo pill
(n=2721)
n=2132 women free of diabetes at baseline 
245 incident cases during trial duration
n=2120 women free of diabetes at baseline
259 incident cases during trial duration
589 prevalent diabetes at 
randomization (excluded)
601 prevalent diabetes at 
randomization (excluded)
FIG. 1. Flow diagram illustrating diabetes outcomes in the randomly assigned treatment of folic acid and vitamins B6 and B12 of the WAFACS.
A total of 1,190 participants who had a diagnosis of diabetes at baseline were excluded in the analysis.
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naires and was deﬁned as taking at least two-thirds of the study pills. Average
adherence over the course of follow-up was 83% for active and placebo
agents, with no signiﬁcant difference between active and placebo groups. Use
of open-label folic acid supplements, vitamin B6, or vitamin B12 supplements
containing more than the recommended daily allowance for at least 4 days per
month ranged from 2 to 11% in the active group to 2 to 13% in the placebo
group over the course of the study. There were no serious adverse events
reported that were conclusively related to study interventions.
Women in the WAFACS provided a baseline blood sample in 1996, prior to
the initiation of background dietary folic acid fortiﬁcation in the U.S. food
supply in 1998. Randomly selected from participants who were adherent with
study medications, 300 (150 in the active treatment and 150 in the placebo
group) provided a blood sample at the end of randomized treatment.
As reported previously (25), median folate and homocysteine levels were
similar between the active treatment group and the placebo group at baseline.
At the end of study follow-up, the median folate level increased signiﬁcantly
in both groups; however, the relative increase in folate level was greater in the
active treatment group. Despite signiﬁcant increases in folate levels among
the placebo group, there was no apparent reduction in homocysteine levels
at the end of the study compared with participants measured at the beginning
of the study in the placebo group (P  0.99). In comparison, homocysteine
levels were signiﬁcantly reduced in the active treatment group; the geometric
mean homocysteine level was decreased by 18.5% (95% CI 12.5–24.1; P 
0.001) in the active group over that observed in the placebo group for a
difference of 2.27 mol/l (1.54–2.96) from the placebo geometric mean
homocysteine level of 12.28 mol/l (25).
Ascertainment of incident type 2 diabetes. Diabetes status was evaluated
at baseline, and all the participants were also asked annually whether and
when they had been diagnosed with diabetes after randomization. Women
who reported a diagnosis of diabetes during the follow-up were mailed
supplementary questionnaires to conﬁrm their self-reported diagnoses. The
supplementary diabetes questionnaire was speciﬁcally designed to collect
further detailed information on diabetes symptoms, screening test, and
hypoglycemic medication. Based on the American Diabetes Association
diagnostic criteria (28), actual glucose levels at fasting or oral glucose
tolerance testing, diabetic symptoms, and/or hypoglycemic medication were
combined together to conﬁrm the self-reported incident cases of diabetes in a
blinded fashion. The screening rate of having blood glucose testing among our
study population was relatively high (85–90%). The observed high agreement
between annual follow-up questionnaire and supplementary questionnaire
(positive predictive value  96%) suggests that self-reported diabetes pos-
sesses excellent predictive ability for true diabetes status in this cohort of U.S.
female health professionals, who are likely to report accurate diagnostic
information (29). Thus, we believe that self-reported type 2 diabetes is valid in
our study population.
Statistical analysis. Primary analyses were performed on an intention-to-
treat basis, including all randomized women after excluding those with
self-reported diabetes at baseline. Baseline characteristics were compared by
randomized groups using two-sample t tests for continuous variables and 
2
statistics for categorical variables. Kaplan-Meier survival curves were used to
estimate the overall cumulative incidence over time for the active vitamin
group and the placebo group. The log-rank test was computed to compare the
curves. We used Cox proportional hazards models to calculate the estimates
of hazard ratio expressed as relative risks (RRs) and 95% CI for randomized
treatment versus placebo, after adjustment for age and other randomized
treatments (vitamin E, vitamin C, and -carotene). To test the proportionality
assumption, we included an interaction term for treatment with the logarithm
of time in the Cox models. The tests showed that the proportional hazard
assumption was not violated for any of the models. To examine the effect of
actual as opposed to assigned folic acid/B vitamin treatment, we carried out
a sensitivity analysis according to compliance. Women were censored if and
when they stopped taking at least two-thirds of their study pills or were
missing compliance information.
Subgroup analyses were conducted to examine the effect of active treat-
ment on risk of type 2 diabetes according to prespeciﬁed risk factors for type
2 diabetes at baseline, including age-groups (45–54, 55–64, and 65 years),
BMI (kg/m
2), smoking status (current, past, or never), alcohol use (never/
rarely or one or more drinks per month), family history of diabetes (yes or no),
physical activity (estimated energy expenditure from leisure activities of
1,000 or 1,000 kcal per week), menopausal status and hormone therapy
(uncertain menopausal status, premenopausal, or postmenopausal including
current, past, or never users of hormone therapy), history of hypertension (yes
or no), history of hyperlipidemia (yes or no), and baseline dietary intakes of
folate, vitamin B6, or vitamin B12 (tertiles for each). We assessed effect
modiﬁcation using interaction terms between subgroup indicators and ran-
domized assignment, testing for trend when subgroup categories were ordinal.
All analyses were conducted with SAS version 9 (SAS Institute, Cary, NC), and
a two-sided test with a signiﬁcance level of 0.05 (P  0.05) was used.
RESULTS
During a median follow-up period of 7.3 years, 504 women
were diagnosed with type 2 diabetes among 4,252 nondi-
abetic participants who underwent randomization in the
WAFACS. There were no statistically signiﬁcant differ-
ences in baseline characteristics between the folic acid/B
vitamin active treatment group and its corresponding
placebo group (Table 1).
Overall, there was no signiﬁcant effect of folic acid/B
vitamins on the development of type 2 diabetes compared
with the placebo group (Table 2 and Fig. 2). In total, there
were 245 incident cases (11.5%) in the active treatment
group and 259 (12.2%) in the placebo group (172.5/10,000
person-years vs. 184.8/10,000 person-years), correspond-
ing to an overall RR of 0.94 (95% CI 0.79–1.11; P  0.46)
after controlling for age and antioxidant treatment assign-
ments (Table 2). Figure 2 shows the cumulative incidence
of type 2 diabetes events among women in the treatment
and placebo groups by year of follow-up. There appeared
to be a trend toward a modest reduction in risk of type 2
diabetes for the treatment group versus placebo group
over the follow-up period, but the log-rank test for the
overall difference was not statistically signiﬁcant (P for
log-rank test  0.44) (Fig. 2).
When we subdivided the period of risk into years 1 and
2 combined and year 3 onward combined, we did not
observe a statistically signiﬁcant effect in any time period
(Table 2). In sensitivity analyses to minimize potential bias
due to the inclusion of undiagnosed diabetes at baseline,
folic acid/B vitamin treatment was not signiﬁcantly asso-
ciated with risk of type 2 diabetes when excluding those
cases that occurred in the ﬁrst 2 years (RR 0.98 [95% CI
0.80–1.21]; P  0.87). In a separate analysis where women
were censored at the time they stopped taking at least
two-thirds of their study pills or started to use outside folic
acid/B vitamin supplements on 4 days per month, ﬁnd-
ings were similarly nonsigniﬁcant (0.92 [0.76–1.10]; P 
0.36). The results were unchanged after further adjustment
for diabetes risk factors including BMI, physical activity,
family history of diabetes, smoking, postmenopausal hor-
mone use, multivitamin use, alcohol intake, and coffee
consumption.
To determine whether certain subgroups of women
were at particularly high or low risk for type 2 diabetes
with folic acid/B vitamin treatment, we conducted multi-
ple subgroup analyses stratiﬁed by several prespeciﬁed
diabetes risk factors (Fig. 3). Overall, there was no evi-
dence that any of these factors modiﬁed the treatment
effect on the risk of type 2 diabetes. Similarly, neither
baseline dietary folate intake nor intake of vitamin B6 or
vitamin B12 modiﬁed the treatment effect. There was a
signiﬁcant reduction in risk of type 2 diabetes among
women who had a family history of diabetes (RR 0.77 [95%
CI 0.60–0.99]; P  0.04) but not among those who had no
such family history (1.09 [0.85–1.41]; P  0.49), and the
interaction was marginally signiﬁcant (P  0.06). How-
ever, these results from such subgroup analyses should be
treated with caution, since they could be explained by
chance alone due to multiple comparisons or imbalance of
diabetes risk factors at baseline in small subgroups. Fi-
nally, we did a separate analysis to assess whether the
randomly assigned treatment with vitamin E, vitamin C, or
-carotene may have modiﬁed the results (Table 3). We
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any of the subgroups and no evidence for interaction by
the other interventions.
DISCUSSION
In this large, randomized, double-blind, placebo-controlled
trial with 7.3 years of treatment among 4,252 women at
TABLE 1
Baseline characteristics of nondiabetic women according to randomized groups in the WAFACS
Characteristics n
Folic acid and B vitamins
P value Active (n  2,132) Placebo (n  2,120)
Age (years) 4,252 63.1 	 8.9 62.9 	 8.9 0.42
45–54 893 20.4 21.7
55–64 1,526 37.1 34.7
65 1,833 42.6 43.6
BMI (kg/m
2) 4,252 29.7 	 6.4 29.8 	 6.3 0.56
25 1,078 26.6 24.1
25 to 30 1,276 29.2 30.8
30 1,898 44.1 45.1
Smoking status 0.64
Current 519 12.0 12.5
Past 1,846 43.0 43.9
Never 1,887 45.1 43.7
Alcohol use 0.33
Never/rarely 2,102 48.6 50.3
At least one drink/month 565 13.8 12.7
1–6 drinks/week 1,156 28.0 26.4
Daily 429 9.62 10.6
Physical activity (kcal/week) 4,252 1,270 	 1,768 1,209 	 1,700 0.25
1,000 2,681 62.5 63.6

1,000 1,571 37.5 36.4
Menopause and hormone therapy use 0.58
Premenopausal 269 5.86 6.79
Uncertain 91 2.25 2.03
Postmenopausal, current hormone therapy use 2,221 52.8 51.7
Postmenopausal with no hormone therapy use 1,671 39.1 39.5
Family history of diabetes 0.99
Yes 1,450 35.7 35.6
No 2,618 64.4 64.4
Baseline dietary intake
Folic acid (mg) 4,053 492 	 243 494 	 240 0.60
Vitamin B6 (mg) 4,053 4.93 	 15.3 5.19 	 16.0 0.94
Vitamin B12 (mcg) 4,053 8.81 	 8.75 8.83 	 8.44 0.82
Data are means 	 SD unless otherwise indicated.
TABLE 2
RRs of self-reported type 2 diabetes by randomized folic acid and B vitamins intervention in the WAFACS
Number of events/number of
participants (%) RR (95% CI)
Active (n  2,132) Placebo (n  2,120) Age-adjusted model*
Multivariate-adjusted
model†
Follow-up interval (years)
1–2 59 (2.77) 72 (3.40) 0.81 (0.58–1.14) 0.79 (0.55–1.12)
3–5 101 (4.74) 101 (4.76) 0.99 (0.75–1.31) 0.97 (0.73–1.28)
0–5 160 (7.50) 173 (8.16) 0.92 (0.74–1.14) 0.89 (0.72–1.11)
5 85 (3.99) 86 (4.06) 0.98 (0.72–1.32) 0.95 (0.70–1.30)
Total 245 (11.5) 259 (12.2) 0.94 (0.79–1.11) 0.91 (0.76–1.09)
Sensitivity analyses
Excluding ﬁrst 2 years 186 (8.72) 187 (8.82) 0.98 (0.80–1.21) 0.97 (0.78–1.19)
Compliance analyses
Taking two-thirds or more of folic
acid/B vitamins/placebo pills 223 (10.5) 238 (11.2) 0.92 (0.76–1.10) 0.87 (0.72–1.05)
*Adjusted for age and other randomized assignments (vitamins C and E and -carotene). †Additionally adjusted for baseline variables,
including BMI, smoking status, postmenopausal hormone use, multivitamin use, alcohol intake, coffee intake, physical activity, and family
history of diabetes.
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homocysteine-lowering treatment by a combination pill of
folic acid and vitamins B6 and B12 on risk of type 2
diabetes. There remained no evidence for a treatment
effect in a sensitivity analysis restricted to women compli-
ant with their study pills over the follow-up period. Our
study provides the ﬁrst randomized trial data regarding the
long-term effect of folic acid/B vitamin supplementation
on the risk of type 2 diabetes, although our ﬁndings remain
to be corroborated by future research.
It has been hypothesized that B vitamins may help
reduce the risk of type 2 diabetes by ameliorating meta-
bolic abnormalities, such as oxidative damage, inﬂamma-
tion, and endothelial dysfunction, which characterize all
phases of insulin resistance and pancreatic -cell function
and are implicated in the development and progression of
type 2 diabetes. Due to their relative safety and low cost,
B vitamin supplements have been targeted as potential
therapeutic agents in previous randomized controlled tri-
als for prevention of vascular diseases in high-risk popu-
lations. In contrast, direct evidence from randomized trials
of B vitamin supplementation for type 2 diabetes has been
very limited. Some (20–23) but not all (30) secondary
prevention trials have suggested that folic acid supplemen-
tation may be effective in the improvement of oxidative
stress (23) and endothelial dysfunction (20–22) in patients
with type 2 diabetes. To our knowledge, no large clinical
trials have speciﬁcally examined homocysteine-lowering
interventions on the primary prevention of type 2 diabetes.
In the present study, we provide evidence that folic acid
and B vitamins have a neutral effect on the risk of type 2
diabetes among nondiabetic women; this is consistent with
the absence of beneﬁt from this intervention in lowering risk
of cardiovascular events (31). Given the efﬁcacy of the
intervention in reducing homocysteine levels, our trial casts
doubt on the etiologic role of hyperhomocysteinemia in the
development of type 2 diabetes.
A major concern has been raised about the limited effect
of folic acid treatment in a folate-fortiﬁed population. To
assess the changes in homocysteine levels in response to
background folate fortiﬁcation in the U.S. population and
to the randomized treatment with folic acid and B vitamins
in our trial, Albert et al. (25) have conducted an analysis of
baseline and follow-up folate and homocysteine levels in a
randomly chosen subpopulation (150 in the active group
and 150 in the placebo group) of WAFACS participants.
The prefortiﬁcation prevalence of hyperhomocysteinemia
(15.0 mol/l) in our population (27.7%) was larger than
the average prevalence estimates of increased homocys-
teine levels (13.0 mol/l) for men and women (25%) in
the National Health and Nutrition Examination Survey
(32) and in the Framingham population (19%) (33). Despite
signiﬁcant elevation in plasma folate levels due to manda-
tory folate fortiﬁcation, homocysteine levels changed rel-
atively little over a 7-year period. In contrast, our folic
acid/B vitamin intervention lowered homocysteine levels
by 18.5% (2.27 mol/l) (25). This reduction in homocys-
teine levels, however, was not associated with protection
against the development of type 2 diabetes in this random-
ized trial. It is unknown whether a greater magnitude of
homocysteine-lowering would have conferred protection
against diabetes.
Genetic variations in enzymes involved in homocysteine
metabolism may modulate the effect of treatment on risk
of type 2 diabetes via their effects on circulating homocys-
teine levels (34). Interindividual genetic variability in our
study population is an unlikely explanation for our null
ﬁndings, however, because genetic factors should have
been comparable in the active treatment and placebo
groups by the randomization procedure. There may be
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FIG. 2. Cumulative incidence of self-reported type 2 diabetes by randomized treatment assignment (active treatment versus placebo) in the
WAFACS.
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Relative Risk for Type 2 Diabetes
Subgroup
Folic Acid/B Vitamin 
Active Group
Placebo 
Group
P value for 
Interaction
Age (years)
45-54                                                57 (0.13)     80 (0.17)
No. of cases (%) 
55-64                                                94 (0.12)     95 (0.13)
≥65                                                   94 (0.10)     84 (0.09)
<25.0                                                 8 (0.01)      19 (0.04)
25.0-29.9                                         62 (0.10)      52 (0.08)
≥30.0                                             175 (0.19)    188 (0.20)
BMI (kg/m2)
High, >1000kcal/wk                        74 (0.09)     80 (0.10) 
Low, ≤1000kcal/wk 171 (0.13)   179 (0.13)
Physical Activity
0.36
0.85
0.60
Current                                            29 (0.11)      39 (0.15)
Past                                                106 (0.12)    113 (0.12)
Never   110 (0.11)    107 (0.12)
Cigarette Smoking 
0.61
Never/rarely                                  147 (0.14)    157 (0.14)
≥ 1 drink/mon 98 (0.09)     105 (0.10)
Alcohol Intake
0.59
Premenopausal                                 13 (0.10)        20 (0.14)
Postmenopausal, current HT use 133 (0.12)      125 (0.11)
Menopausal status and HT use
0.72
Postmenopausal, no HT use 91 (0.11)     106 (0.13)
Yes                                               110 (0.15)     140 (0.19)
No                    123 (0.09)     113 (0.09)
Family History of diabetes 
0.06
0.71 Tertile 1 (0.12-5.25)                                78 (0.11)       75 (0.11)
Tertile 2 (5.26-9.28) 81 (0.12)       87 (0.13)
Baseline vitamin B12 intake (mcg/d)
Tertile 3 (9.29-207) 72 (0.11)       81 (0.12)
Tertile 1 (0.47-2.00)                                76 (0.11)        77 (0.12)
Tertile 2 (2.01-3.28) 83 (0.12)        87 (0.13)
Baseline vitamin B6 intake (mg/d)
Tertile 3 (3.29-202) 72 (0.11)        79 (0.11)
Tertile 1 (74-347)                                78 (0.11)        82 (0.12)
Tertile 2 (348-570) 82 (0.12)        82 (0.12)
Baseline folate intake (mcg/d)
Tertile 3 (571-2353) 71 (0.11)        79 (0.12)
0.90
0.99
FIG. 3. RRs of self-reported type 2 diabetes by randomized intervention (active treatment versus placebo) within subgroups in the WAFACS. HT,
hormone therapy.
TABLE 3
RRs of self-reported type 2 diabetes by homocysteine-lowering intervention according to other randomized treatment assignment
groups in the WAFACS
Subgroups
Number of events/number of participants (%) RR (95% CI)
Active group Placebo group Age-adjusted model*
P value for
interaction
Vitamin C
Active 114/1,059 (0.11) 119/1,059 (0.11) 0.95 (0.74–1.23) 0.86
Placebo 131/1,073 (0.12) 140/1,061 (0.13) 0.92 (0.73–1.17)
Vitamin E
Active 132/1,067 (0.12) 140/1,038 (0.13) 0.91 (0.72–1.16) 0.77
Placebo 113/1,065 (0.11) 119/1,082 (0.11) 0.96 (0.74–1.24)
-carotene
Active 113/1,077 (0.10) 128/1,040 (0.12) 0.83 (0.65–1.07) 0.21
Placebo 132/1,055 (0.13) 131/1,080 (0.12) 1.04 (0.82–1.33)
*Adjusted for age and two randomized assignments other than stratiﬁed groups.
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genetic variants in the pathway of homocysteine metabo-
lism that could particularly beneﬁt from homocysteine-
lowering therapy. Future well-designed and large-scale
genetic studies within randomized trial settings are war-
ranted to test the hypothesis. Of interest, our prespeciﬁed
subgroup analyses showed a trend toward decreased risk
associated with folic acid/vitamins B6 and B12 among
women with a family history of diabetes, but these ﬁndings
may have been due to chance and need to be conﬁrmed in
future investigations.
Some limitations of our trial also deserve consider-
ation. First, declining compliance over time in the trial
may have diluted the ﬁndings. In sensitivity analyses
restricted to women compliant with their study pills,
however, the overall null effects and trends were un-
changed. Second, the use of a combination pill did not
allow us to investigate the effects of individual compo-
nents or potential interactions among them in relation
to type 2 diabetes. Third, misclassiﬁcation in the self-
reported diagnosis of type 2 diabetes is another con-
cern. Since the proportions of undiagnosed cases are
likely to be similar in the treatment and placebo groups
due to effective randomization and double-blinding
strategies, such a misclassiﬁcation is more likely to be
nondifferential but could have attenuated the results.
Fourth, we did not measure homocysteine and folate
levels in all participants to assess a modifying effect of
baseline levels; however, we found no evidence of
beneﬁts of B vitamin therapy among individuals with
different levels of dietary folate, vitamin B6, and vitamin
B12 intakes at baseline. Fifth, confounding by extrane-
ous risk factors cannot be completely excluded, al-
though the baseline characteristics were well balanced
in the treatment and placebo group, as expected in a
large-scale trial with effective randomization. Finally,
our results based on women at high risk for CVD may
not be generalizable to men or to the general population.
In conclusion, in this study within a large, randomized,
placebo-controlled trial among over 5,400 women at high
risk for CVD, we observed no apparent beneﬁt or harm of
folic acid and vitamins B6 and B12 supplementation on the
risk of type 2 diabetes over 7 years of treatment. Our
ﬁndings do not support recommending B vitamin supple-
ments for diabetes prevention, although additional evi-
dence from future large trials in populations with
moderate-to-severe hyperhomocysteinemia or in regions
without grain fortiﬁcation will be needed.
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